Biotechnology company Novavax (NASDAQ:NVAX) delivered mixed results for the third quarter of 2022 and revised its full-year revenue guidance to reflect the lower demand for COVID-19 vaccines. The company’s net loss per share narrowed to $2.15 from $4.31 in the prior-year quarter, but significantly missed analysts’ expectations of earnings per share of $1.57. Novavax shares rose over 2% initially in Wednesday’s extended trading session but pared some gains later. NVAX stock has plunged over 86% year-to-date. Meanwhile, the company’s Q3 revenue jumped 311% to $735 million, mainly due to the sale of 35 million doses of its NVX-CoV2373 COVID-19 vaccine. Q3 revenue handily surpassed analysts’ estimate of $586 million.
https://www.tipranks.com/news/novavax-nasdaqnvax-posts-mixed-q3-results-revises-outlook-on-waning-vaccine-demand?utm_source=advfn.com&utm_medium=referral
Novavax (NASDAQ:NVAX)
Historical Stock Chart
Von Jan 2023 bis Feb 2023 Click Here for more Novavax Charts.
Novavax (NASDAQ:NVAX)
Historical Stock Chart
Von Feb 2022 bis Feb 2023 Click Here for more Novavax Charts.